Mar 2, 2026 08:25AM
Mar 2, 2026 08:25AM
Nov 17, 2025 08:35AM
Aug 15, 2025 08:05AM
Jun 5, 2025 08:05AM
May 16, 2025 08:05AM
May 13, 2025 07:04AM CNS Pharmaceuticals (CNSP) Acquires Orphan Drug Designation for TPI 287
May 13, 2025 07:00AM
Apr 1, 2025 08:05AM
Feb 18, 2025 09:00AM
Nov 25, 2024 09:02AM
Nov 25, 2024 09:00AM
Nov 15, 2024 09:10AM
Aug 15, 2024 08:00AM CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results
Jul 30, 2024 07:05AM
Jul 30, 2024 07:00AM
May 16, 2024 07:45AM
Apr 1, 2024 04:26PM
Jan 18, 2024 08:46AM
Jan 18, 2024 08:45AM
Jan 17, 2024 08:45AM CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Dec 18, 2023 08:40AM
Dec 18, 2023 08:35AM
Dec 6, 2023 09:00AM
Nov 22, 2023 09:08AM
Nov 22, 2023 09:05AM
Nov 16, 2023 10:00AM
Nov 15, 2023 08:00AM CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End
Oct 16, 2023 09:00AM
Oct 11, 2023 08:45AM
Sep 7, 2023 08:45AM
Aug 14, 2023 08:39AM
Aug 14, 2023 08:35AM
Aug 3, 2023 08:04AM
Aug 3, 2023 08:00AM CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
May 25, 2023 09:05AM
Apr 10, 2023 08:45AM
Apr 6, 2023 09:05AM
Apr 3, 2023 08:05AM
Mar 9, 2023 09:05AM
Mar 9, 2023 09:05AM
Feb 7, 2023 08:45AM CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
Dec 8, 2022 09:11AM
Dec 8, 2022 09:08AM
Nov 14, 2022 04:05PM
Nov 2, 2022 08:45AM
Oct 7, 2022 08:00AM
Sep 28, 2022 09:05AM
Sep 23, 2022 09:00AM CNS Pharmaceuticals to Present at the Virtual Investor Innovations in Oncology - Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (GBM)
Aug 15, 2022 08:05AM

322,084 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All